Navigation Links
Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy

Milwaukee, WI (PRWEB) August 27, 2013

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma has been released by the Society for Immunotherapy of Cancer (SITC) and published online by Nature Reviews Clinical Oncology. Essentially a road map for using immunotherapy to treat patients with melanoma, this consensus statement known as the “Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” provides patients and physicians alike with expert evidence-based recommendations for the use of different immunotherapies including interferon-a2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. Recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapy, are also provided in this statement.

“Cancer immunotherapy is a rapidly advancing form of cancer treatment that has induced durable therapeutic responses in a subset of patients with advanced melanoma,” Michael Atkins, MD, Georgetown-Lombardi Comprehensive Cancer Center and a co-author on the paper said. “Current data suggests that cancer immunotherapy is being underutilized and many patients who might benefit from immunotherapy are not given the opportunity in the optimal setting. The goal of these guidelines is to change that and to provide a readily available and comprehensive resource about how and when to consider immunotherapy for patients with melanoma.”

Prior to the consensus statement’s publication, the lack of evidence-based guidelines in the field created obstacles and discord for practicing oncologists in the treatment of patients with melanoma. Now, this statement provides the best available evidence and consensus thinking for those interested in pursuing treatment with immunotherapy.

“The SITC consensus statement addresses the knowledge gaps and creates a standard set of guiding principles for oncologists set forth for the effective and efficient application of cancer immunotherapy for patients with melanoma,” Howard L. Kaufman, MD, FACS, Rush University Medical Center and corresponding author on the paper said. “The group of authors who developed this statement considered the strength of the evidence for key issues in the field and provided consensus recommendations in these areas; especially where data was weak or missing.”

This consensus statement was created from work done by the SITC Cancer Immunotherapy Guidelines (CIG) Task Force established in 2010 and made up of more than 30 experts in the field of melanoma. The task force utilized the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for the consensus statement. However, as cancer immunotherapy continues to rapidly develop, the SITC Melanoma CIG Task Force will update the consensus statement as new findings and results from on-going clinical trials or as the approval of drugs from the FDA for the treatment of melanoma are released.

To read “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” visit:

For more information on the consensus statement and the Society for Immunotherapy of Cancer, visit:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
4. Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
5. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
6. JTCC researchers play important role in groundbreaking study that may change transplant practices
7. MyPuress Releases Details About Groundbreaking New Product
8. Rectal microbicide research takes giant leap forward with groundbreaking educational video
9. Skin Authority Creates One-of-a-Kind Solution for the One Billion People Worldwide Who are Vitamin D Deficient -- Groundbreaking Launch of "Inside Out" System
10. Groundbreaking Training Video Prepares Surgical Team to Become Safest in the U.S.
11. Groundbreaking UK study shows key enzyme missing from aggressive form of breast cancer
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... The men and women on this ... in the country. They have overseen financial turnarounds, shown commitment to their community ... industry as a whole through their advocacy and professional efforts. , Becker's Hospital ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... Nov. 25, 2015  Linden Care, LLC, a retail ... outcomes for patients suffering from chronic pain, said today ... Temporary Restraining Order (TRO) enjoining Express Scripts from unilaterally ... --> --> The ... its legal options. --> ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
Breaking Medicine Technology: